查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179871

2023-2030 年全球自動乳腺超聲機 (ABUS) 市場

Global Automated Breast Ultrasound Systems (ABUS) Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球自動化乳腺超聲機市場規模將在 2023 年達到 14.24 億美元，到 2030 年達到 24.52 億美元，在預測期內（2023-2030 年）以 12.4% 的複合年增長率增長。據預測，

一種更常見的技術，自動乳腺超聲 (ABUS)，可能是乳腺組織緻密（腺體和纖維比脂肪更多）的女性唯一的額外危險因素。它可以多檢測出多達 30% 的腫瘤。 乳房緻密的女性可能會發現乳房 X 光檢查不足，而 ABUS 可以檢測出更多的惡性腫瘤。 ABUS 在超聲期間不使用電離輻射，是一種快速、無痛且有效的緻密乳房成像方法。

市場動態

推動全球自動乳腺超聲機市場的關鍵因素 隨著自動乳腺超聲機技術的進步和對乳腺癌的認識不斷提高，政府的舉措有利於全球乳腺癌發病率的上升，這是市場的最大推動力。

全球乳腺癌患病率上升已成為市場最重要的驅動力。

據世界衛生組織稱，乳腺癌起源於乳房腺體組織的導管 (85%) 或小葉 (15%) 的活細胞（上皮細胞）。 惡性轉化最初局限於導管或小葉，通常無症狀，轉移風險低。 到 2020 年，乳腺癌將導致全球 684,000 人死亡，影響 230 萬女性。 截至 2020 年底，乳腺癌是世界上最常見的癌症，過去五年有 780 萬女性被確診。 乳腺癌是導致全球女性傷殘調整生命年 (DALYs) 損失最多的癌症類型。 乳腺癌發生在世界所有國家青春期後的任何年齡的女性身上，但在以後的生活中更為常見。

據美國癌症協會估計，到 2022 年，將有大約 287,840 例新的女性浸潤性乳腺癌病例、大約 51,400 例新的乳腺癌 (DCIS) 病例以及大約 43,250 例與乳腺癌相關的女性死亡病例。我希望它能成為一個例子。 乳腺癌最常見於中年和老年婦女。 乳腺癌診斷的典型年齡是 62 歲。 因此，女性發現乳腺癌的平均年齡為 62 歲或更小。 乳腺癌在 45 歲以下的女性中極為罕見。

自動乳腺超聲機的高價格阻礙了市場增長。

自動乳腺超聲成像系統的應用受到許多國家/地區嚴格法規的限制。 此外，與傳統癌症篩查方法相比，自動乳腺超聲系統 (ABUS) 的高成本預計將抑制市場擴張。

COVID-19 影響分析

一旦 COVID-19 大流行開始，感染頻率的嚴重程度和傳播速度都會增加。 在全球大流行初期，感染 COVID-19 病毒的患者人數有所增加。 為了減少和控制不同的傳播途徑，醫院已將應急方案作為重中之重。 因此，需要超聲篩查的擇期手術已經減少。 儘管選擇性超聲治療有所下降，但在需要成像服務的緊急程序中使用 X 射線、CT 掃描和超聲的情況有所增加。 由於 COVID-19 的長期影響，預計超聲診斷設備的引入將增加用於專業診斷，尤其是在腎臟和肺部。 在大流行早期，肺部超聲掃描顯示出增加的趨勢。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 增加自動乳腺超聲設備的技術進步
      • 提高對乳腺癌的認識和政府舉措
    • 約束因素
      • 自動乳腺超聲系統的價格更高
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按超聲類型分類

  • 多普勒超聲
  • 彩色多普勒
  • 經陰道超聲

第八章應用

  • 乳房成像
  • 放映

第 9 章最終用戶

  • 醫院
  • 影像診斷中心
  • 診斷實驗室

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • General Healthcare Company
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Hitachi, Ltd
  • Koninklijke Philips N.V.
  • Siemens AG
  • SonoCine Inc
  • Qview Medical
  • Koios Medical
  • Volpara Solutions Limited
  • Delphinus Medical Technologies, Inc.
  • Nova Medical Inc

第13章 DataM

簡介目錄
Product Code: DMMD914

Market Overview

The global automated breast ultrasound systems market size was valued at US$ 14,24 million in 2023 and is estimated to reach US$ 2452 million by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).

A more popular technique, Automated Breast Ultrasound (ABUS), can detect up to 30% more tumors in women with dense breast tissue (more glandular or fibrous than fatty), even if it is the only extra risk factor. Women with denser breasts may make mammography insufficient and can employ ABUS to discover more malignancies. No ionizing radiation is used during ultrasound procedures, and ABUS is a quick, painless, and efficient approach to photographing dense breasts.

Market Dynamics

The major factors driving the global Automated breast ultrasound systems market rising prevalence of breast cancer worldwide is the most significant driving factor of the market, as increasing technological advancements in automated breast ultrasound systems and rising awareness regarding breast cancer favorable government initiatives.

The rising prevalence of breast cancer worldwide is the most significant driving factor in the market.

According to WHO, in the glandular tissue of the breast, breast cancer begins in the living cells (epithelium) of the ducts (85%) or lobules (15%). The malignant development is initially restricted to the duct or lobule, where it often exhibits no symptoms and has a low risk of spreading. 684,000 people worldwide died in 2020 due to breast cancer, which affected 2.3 million women. The most common cancer globally as of the end of 2020 was breast cancer, diagnosed in 7.8 million women in the previous five years. Breast cancer is the form of cancer that results in the most lost disability-adjusted life years (DALYs) for women globally. Breast cancer occurs in every nation of the world in women at any age after puberty but with rising rates in later life.

The American Cancer Society predicts that in 2022, there will be about 287,840 new cases of invasive breast cancer in women, about 51,400 new instances of ductal carcinoma in situ (DCIS), and about 43,250 new cases of breast cancer-related deaths in women. Breast cancer is more common in women in their middle years and older. The typical age at breast cancer diagnosis is 62 years old. The average age at which breast cancer in women is found is therefore 62 years of age or less. Breast cancer diagnoses in women under 45 are incredibly uncommon.

The automated breast ultrasound system's high price will hamper the market's growth.

The application of automated breast ultrasound imaging systems has been constrained by severe rules in a number of nations. Additionally, the high cost of automated breast ultrasound systems (ABUS) compared to traditional cancer screening methods is anticipated to restrain market expansion.

COVID-19 Impact Analysis

Infectious disease frequency increased in terms of the severity and rate of dissemination with the beginning of the COVID-19 pandemic. During the early stages of the global pandemic, the number of patients infected with the COVID-19 virus increased. To decrease and control different infection transmission, hospitals adopted emergency protocols as a top priority. This led to a decline in elective procedures that needed ultrasound screening. The use of X-rays, CT scans, and ultrasounds for emergency procedures that needed imaging services increased despite a reduction in elective ultrasound treatments. The adoption of ultrasound equipment for specialized diagnostics, notably for kidneys and lungs, is anticipated to increase due to COVID-19's long-term effects. The number of ultrasound operations for lungs exhibited a rising trend during the early stages of the pandemic.

Segment Analysis

The hospital's segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ABUS implementation is progressively gaining momentum in more hospitals to meet the patients' diagnostic demands. The demand for ABUS in these healthcare settings will be driven by rising cancer screening test usage among young and middle-aged women. Hospitals are installing ABUS to provide safer diagnostic choices because pregnant women cannot get mammography due to the radiation danger.

Breast cancer surgery involves operating to remove the tumor, which is a crucial part of treatment for the disease. Breast cancer surgery can be used either on its own or in conjunction with other therapies, such as chemotherapy, hormone therapy, targeted therapy, and radiation therapy, administered in a hospital setting under the guidance of a qualified doctor.

Each year, more than 100,000 American women get a mastectomy. Although it is frequently done to treat breast cancer, it is occasionally done to lower the chance of developing breast cancer. Because procedures must be performed in hospitals under the supervision of doctors, the hospital sector drives the market. Compared to general or specialty hospitals, teaching hospitals in several affluent nations have seen a dramatic increase in demand for various treatment modalities. However, the number of new hospitals in developing nations in North America has sharply increased. Imaging modalities typically have their room in new hospitals. Rising competition and rising demand for top-notch medical care are the two main reasons predicted to drive segment expansion.

Geographical Analysis

North America holds the largest market share in the global automated breast ultrasound systems market.

According to the American Society of Cancer, about 281,550 new breast cancer cases will be discovered in women in 2021, and 43,600 women will pass away from the disease. The prevalence of breast cancer is rising, increasing the need for cutting-edge breast imaging equipment and support for efficient therapies. The ABUS market in the U.S. will grow as government campaigns to inform and educate women about breast cancer and the value of screening increase. According to the Breast Cancer Organization, 1 in 8 (or around 13%) American women will eventually develop invasive breast cancer.

In the United States, women are anticipated to receive diagnoses for 287,840 new instances of invasive breast cancer and 51,500 new cases of non-invasive (in situ) breast cancer in 2022. In 2022, it's anticipated that 2,710 new instances of invasive breast cancer will be found in men. About 1 in 833 men may develop breast cancer in their lives. In the U.S., more than 3.8 million women have had breast cancer in the past as of January 2022. Women who have completed treatment and those who are presently receiving it are included. Several foundations in the United States have launched awareness programs, including the Susan Komen Foundation, the National Breast Cancer Foundation, and the American Society of Cancer's National Breast Cancer Awareness (NBCA) month. These will benefit the need for automated breast ultrasonography systems for detecting breast cancer in breast tissue with dense cellularity.

Competitive Landscape

The Automated breast ultrasound systems market is moderately competitive with local and global companies' presence GE Healthcare, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG , SonoCine Inc, Qview Medical, Hologic Inc, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2022, Koios DS, a software platform powered by artificial intelligence (AI) and shown to effectively diagnose thyroid and breast malignancies in ultrasound tests, has received CE Marking under the EU MDR, according to Koios Medical, a pioneer in the field of cancer diagnostics using ultrasound. The innovative dual-diagnosis method, developed utilizing data from a global network of 55 sites, speeds up interpretation, automates reporting, and shortens the time it takes to administer medication while eliminating unnecessary surgery

General Electric Company.

Overview: E Healthcare, a division of General Electric Company, is a global provider of medical devices that creates, develops, produces, and sells diagnostic imaging and clinical systems, as well as a variety of healthcare IT solutions, products and services for drug discovery, biopharmaceutical production, and cellular technologies. Additionally, GE Healthcare offers services including computerized data management, remote diagnostic and repair services for medical equipment made by the business and others, performance enhancement and performance solutions services, and other services.

Product Portfolio:

Invenia ABUS 2.0: One of the biggest widespread risk factors for getting breast cancer is having thick breasts, which affects about 40% of women. The clinical data supporting the use of ultrasonography to detect tiny, node-negative, invasive tumors that mammography misses is emerging. For dense breast imaging in the screening context, Invenia ABUS 2.0 supplemental imaging is designed.

The global automated breast ultrasound systems market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing technological advancements in automated breast ultrasound systems
      • 4.1.1.2. Rising awareness regarding breast cancer and favorable government initiatives
    • 4.1.2. Restraints:
      • 4.1.2.1. The automated breast ultrasound system's high price
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ultrasound Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 7.1.2. Market Attractiveness Index, By Ultrasound Type
  • 7.2. Doppler ultrasound
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Color Doppler
  • 7.4. Transvaginal ultrasound

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Breast imaging
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Screening

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Imaging Centers
  • 9.4. Diagnostic Laboratories

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. General Healthcare Company
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Hitachi, Ltd
  • 12.3. Koninklijke Philips N.V.
  • 12.4. Siemens AG
  • 12.5. SonoCine Inc
  • 12.6. Qview Medical
  • 12.7. Koios Medical
  • 12.8. Volpara Solutions Limited
  • 12.9. Delphinus Medical Technologies, Inc.
  • 12.10. Nova Medical Inc

LIST NOT EXHAUSTIVE

13. Global Automated breast ultrasound systems Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us